LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

ON-TREATMENT LDL-C LEVELS WHEN ALIROCUMAB DOSE IS DECREASED FROM 150 TO 75 MG EVERY 2 WEEKS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM ODYSSEY OLE

Photo by nci from unsplash

Background: Alirocumab (ALI) is available in two doses, 75 and 150 mg (to be administered once every 2 weeks [Q2W]). ODYSSEY LONG TERM was a 78-week double-blind trial of ALI… Click to show full abstract

Background: Alirocumab (ALI) is available in two doses, 75 and 150 mg (to be administered once every 2 weeks [Q2W]). ODYSSEY LONG TERM was a 78-week double-blind trial of ALI 150 mg Q2W versus placebo, as add-on to maximally tolerated statin ± other lipid-lowering therapy (LLT). Patients with

Keywords: alirocumab dose; treatment ldl; every weeks; dose decreased; levels alirocumab; ldl levels

Journal Title: Journal of the American College of Cardiology
Year Published: 2017

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.